As of 2024-07-27, the EV/EBITDA ratio of Neurocrine Biosciences Inc (NBIX) is 29.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NBIX's latest enterprise value is 14,500.45 mil USD. NBIX's TTM EBITDA according to its financial statements is 496.40 mil USD. Dividing these 2 quantities gives us the above NBIX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 18.4x - 28.8x | 24.3x |
| Forward P/E multiples | 25.2x - 34.7x | 30.6x |
| Fair Price | 84.33 - 144.67 | 112.24 |
| Upside | -42.6% - -1.4% | -23.5% |
| Date | EV/EBITDA |
| 2024-07-26 | 29.21 |
| 2024-07-25 | 29.07 |
| 2024-07-24 | 29.02 |
| 2024-07-23 | 28.94 |
| 2024-07-22 | 28.90 |
| 2024-07-19 | 28.99 |
| 2024-07-18 | 28.67 |
| 2024-07-17 | 28.78 |
| 2024-07-16 | 29.34 |
| 2024-07-15 | 29.35 |
| 2024-07-12 | 29.34 |
| 2024-07-11 | 29.15 |
| 2024-07-10 | 29.28 |
| 2024-07-09 | 28.50 |
| 2024-07-08 | 28.29 |
| 2024-07-05 | 27.65 |
| 2024-07-03 | 27.47 |
| 2024-07-02 | 27.32 |
| 2024-07-01 | 27.85 |
| 2024-06-28 | 27.36 |
| 2024-06-27 | 26.68 |
| 2024-06-26 | 26.99 |
| 2024-06-25 | 26.84 |
| 2024-06-24 | 26.54 |
| 2024-06-21 | 26.73 |
| 2024-06-20 | 26.63 |
| 2024-06-18 | 25.98 |
| 2024-06-17 | 26.88 |
| 2024-06-14 | 26.91 |
| 2024-06-13 | 27.07 |
| 2024-06-12 | 26.74 |
| 2024-06-11 | 26.44 |
| 2024-06-10 | 26.76 |
| 2024-06-07 | 26.81 |
| 2024-06-06 | 26.43 |
| 2024-06-05 | 26.55 |
| 2024-06-04 | 26.51 |
| 2024-06-03 | 27.82 |
| 2024-05-31 | 26.90 |
| 2024-05-30 | 27.16 |
| 2024-05-29 | 26.74 |
| 2024-05-28 | 27.93 |
| 2024-05-24 | 27.71 |
| 2024-05-23 | 27.94 |
| 2024-05-22 | 27.72 |
| 2024-05-21 | 27.94 |
| 2024-05-20 | 28.17 |
| 2024-05-17 | 28.30 |
| 2024-05-16 | 28.22 |
| 2024-05-15 | 28.24 |